Alphamab Oncology (HKG:9966)
7.70
-0.04 (-0.52%)
At close: Mar 27, 2026
Alphamab Oncology Revenue
In the year 2025, Alphamab Oncology had annual revenue of 566.24M CNY, down -11.54%. Alphamab Oncology had revenue of 319.44M in the half year ending June 30, 2025, with 134.08% growth.
Revenue
566.24M CNY
Revenue Growth
-11.54%
P/S Ratio
11.84
Revenue / Employee
1.17M CNY
Employees
484
Market Cap
7.46B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 566.24M | -73.85M | -11.54% |
| Dec 31, 2024 | 640.08M | 421.31M | 192.58% |
| Dec 31, 2023 | 218.77M | 51.93M | 31.12% |
| Dec 31, 2022 | 166.85M | 20.82M | 14.26% |
| Dec 31, 2021 | 146.02M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Shanghai Haohai Biological Technology | 2.75B |
| Lepu Biopharma | 1.04B |
| HBM Holdings | 908.35M |
| Ocumension Therapeutics | 895.09M |
| Abbisko Cayman | 681.17M |
| Guangzhou Innogen Pharmaceutical Group | 146.34M |
| CARsgen Therapeutics Holdings | 139.84M |
Alphamab Oncology News
- 3 months ago - Alphamab Oncology's JSKN033 Cleared For Phase 2 Cervical Cancer Trial By Chinese Regulatory Agency - Nasdaq